Measures · D13 in 2017 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Medication Adherence for Hypertension (RAS antagonists)
Drug PlanMedication AdherenceSource: Prescription Drug Events
- What it measures
- Percent of plan members with a prescription for a blood pressure medication who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication. One of the most important ways people with high blood pressure can manage their health is by taking medication as directed. The plan, the doctor, and the member can work together to do this. (“Blood pressure medication” means an ACE (angiotensin converting enzyme) inhibitor, an ARB (angiotensin receptor blocker), or a direct renin inhibitor drug.
- How it's calculated
- This measure is defined as the percent of Medicare Part D beneficiaries 18 years and older who adhere to their prescribed drug therapy for renin angiotensin system (RAS) antagonists: angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or direct renin inhibitor medications. This percentage is calculated as the number of member-years of enrolled beneficiaries 18 years and older with a proportion of days covered (PDC) at 80 percent or higher for RAS antagonist medications during the measurement period (numerator) divided by the number of member-years of enrolled beneficiaries 18 years and older with at least two fills of either the same medication or medications in the drug class during the measurement period (denominator). The PDC is the percent of days in the measurement period “covered” by prescription claims for the same medication or another in its therapeutic category. Beneficiaries with ESRD coverage dates or that received one or more prescriptions for sacubitril/valsartan anytime during the measurement period are excluded. Beneficiaries are only included in the measure calculation if the first fill of their medication occurs at least 91 days before the end of the enrollment period. The Part D Medication Adherence measure is adapted from the Medication Adherence- Proportion of Days Covered measure that was developed and endorsed by the Pharmacy Quality Alliance (PQA). The PDC Adherence measures are also endorsed by the National Quality Forum (NQF). See the medication list for this measure. The Part D Medication Adherence rate is calculated using the National Drug Code (NDC) list and obsolete NDC date methodology maintained by the PQA. The complete NDC list is posted along with these technical notes. NDCs with obsolete dates are included in the measure calculation if the obsolete dates as reported by PQA are within the period of measurement (measurement year) or within six months prior to the beginning of the measurement year.
- Data source
- Prescription Drug Event (PDE) data The data for this measure come from PDE data files submitted by drug plans to Medicare for January 1, 2015-December 31, 2015 by June 30, 2016. Only final action PDE claims are used to calculate this measure. PDE claims are limited to members who received at least two prescriptions on unique dates of service for RAS antagonist medication(s). PDE adjustments made post-reconciliation are not reflected in this measure. Additional data sources include the Common Medicare Environment (CME), the Medicare Enrollment Database (EDB), and the Common Working File (CWF). • CME is used for enrollment information. • EDB is used for hospice enrollment and ESRD status (using the ESRD indicator). • CWF is used to identify inpatient stays for PDPs and MA-PDs, and skilled nursing facility stays for PDPs.
- Measurement period
- 01/01/2015 - 12/31/2015
- Better when
- Higher
- Weight
- 3 (Intermediate Outcome Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- —
- In improvement measure
- Yes
- Used in CAI
- Yes
- Exclusions
Show
Contracts with 30 or fewer enrolled member-years (in the denominator)- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the medication or NDC lists, are excluded from CMS analyses. Also, the member-years of enrollment adjustment is made by CMS to account for partial enrollment within the benefit year. Enrollment is measured at the episode level, and inclusion in the measure is determined separately for each episode – i.e., to be included for a given episode, the beneficiary must meet the initial inclusion criteria for the measure during that episode. The measure is weighted based on the total number of member years for each episode in which the beneficiary meets the measure criteria. For instance, if a beneficiary is enrolled for a three-month episode, disenrolled for a six-month episode, reenrolled for a three-month episode, and meets the measure criteria during each enrollment episode, s/he will count as 0.5 member years in the rate calculation (3/12 + 3/12 = 6/12). The PDC calculation is adjusted for overlapping prescriptions for the same drug which is defined by active ingredient at the generic name level using the Medi-Span generic ingredient name. The calculation also adjusts for Part D beneficiaries’ stays in inpatient (IP) settings, hospice enrollments, and stays in skilled nursing facilities (SNFs). The SNF adjustment only applies to PDPs because SNF data are not currently available for MA-PDs. Please see Attachment L: Medication Adherence Measure Calculations for more information about these calculation adjustments. When available, beneficiary death date from the CME is the end date of a beneficiary’s measurement period.
From the 2017 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 84 | 85 | +1 |
| 3★ | MA-PD | 88 | 89 | +1 |
| 4★ | MA-PD | 90 | 91 | +1 |
| 5★ | MA-PD | 93 | 94 | +1 |
| 2★ | PDP | 87 | 88 | +1 |
| 3★ | PDP | 89 | 90 | +1 |
| 4★ | PDP | 90 | 91 | +1 |
| 5★ | PDP | 92 | 92 | 0 |
2017 star distribution
Not rated: No data available (63); Plan too new to be measured (61); Plan not required to report measure (13); Not enough data available (5)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 90 % | >= 90 % to < 93 % | >= 93 % |
| 2027 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2026 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 91 % | >= 91 % to < 93 % | >= 93 % |
| 2026 | PDP | < 88 % | >= 88 % to < 90 % | >= 90 % to < 91 % | >= 91 % to < 93 % | >= 93 % |
| 2025 | MA-PD | < 83 % | >= 83 % to < 87 % | >= 87 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2025 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2024 | MA-PD | < 82 % | >= 82 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2024 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 91 % | >= 91 % to < 94 % | >= 94 % |
| 2023 | MA-PD | < 78 % | >= 78 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2023 | PDP | < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % to < 96 % | >= 96 % |
| 2022 | MA-PD | < 74 % | >= 74 % to < 82 % | >= 82 % to < 87 % | >= 87 % to < 90 % | >= 90 % |
| 2022 | PDP | < 85 % | >= 85 % to < 88 % | >= 88 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2021 | MA-PD | < 80 % | >= 80 % to < 84 % | >= 84 % to < 87 % | >= 87 % to < 89 % | >= 89 % |
| 2021 | PDP | < 84 % | >= 84 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 90 % | >= 90 % |
| 2020 | MA-PD | < 80% | ? 80% to < 83% | ? 83% to < 86% | ? 86% to < 88% | ? 88% |
| 2020 | PDP | < 83% | ? 83% to < 85% | ? 85% to < 88% | ? 88% to < 90% | ? 90% |
| 2019 | MA-PD | < 79% | ? 79% to < 83% | ? 83% to < 86% | ? 86% to < 88% | ? 88% |
| 2019 | PDP | < 84% | ? 84% to < 86% | ? 86% to < 87% | ? 87% to < 89% | ? 89% |
| 2018 | MA-PD | < 74% | ? 74% to < 78% | ? 78% to < 82% | ? 82% to < 85% | ? 85% |
| 2018 | PDP | < 78% | ? 78% to < 83% | ? 83% to < 86% | ? 86% to < 89% | ? 89% |
| 2017 | MA-PD | < 71% | ? 71% to < 75% | ? 75% to < 79% | ? 79% to < 83% | ? 83% |
| 2017 | PDP | < 77% | ? 77% to < 80% | ? 80% to < 83% | ? 83% to < 85% | ? 85% |
| 2016 | MA-PD | < 58% | ? 58% to < 73% | ? 73% to < 77% | ? 77% to < 81% | ? 81% |
| 2016 | PDP | < 76% | ? 76% to < 78% | ? 78% to < 82% | ? 82% to < 85% | ? 85% |
| 2015 | MA-PD | < 72% | ? 72% to < 76% | ? 76% to < 81% | ? 81% to < 85% | ? 85% |
| 2015 | PDP | < 72% | ? 72% to < 76% | ? 76% to < 81% | ? 81% to < 84% | ? 84% |
Lowest-scoring contracts, 2017
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| S0522 Symphonix Health Insurance, Inc. | UnitedHealth Group, Inc. | — | 72 | 1 | −1 | 11 | 0% |
| H8266 Constellation Health, Llc. | Constellation Health, LLC. | — | 59 | 1 | 0 | 20 | 0% |
| H7960 HARBOR HEALTH PLAN, INC. | Tenet Healthcare Corporation | — | 61 | 1 | — | 18 | 0% |
| H4876 Constellation Health, Llc. | Constellation Health, LLC. | — | 63 | 1 | — | 16 | 0% |
| H0490 Molina Healthcare Of Ohio, Inc. | Molina Healthcare, Inc., | — | 67 | 1 | −1 | 12 | 1% |
| H3071 Clear Spring Health | Group 1001 | — | 68 | 1 | −1 | 11 | 1% |
| H5587 Blue Cross Blue Shield of Arizona Health Choice | Blue Cross Blue Shield of Arizona | 8,603 | 68 | 1 | −1 | 11 | 1% |
| H8170 America's 1st Choice Of South Carolina, Inc. | Anthem Inc. | — | 68 | 1 | — | 11 | 1% |
| H1112 Wellcare | Centene Corporation | 25,885 | 68 | 1 | −1 | 11 | 1% |
| S7694 Elixir Insurance | Rite Aid Corporation | — | 75 | 1 | 0 | 8 | 2% |
| H5992 Senior Whole Health of New York | Molina Healthcare, Inc. | 1,578 | 69 | 1 | — | 10 | 2% |
| H9730 Wellcare | Centene Corporation | 35,990 | 70 | 1 | −1 | 9 | 2% |
| H6988 Anthem Blue Cross and Blue Shield HP | Elevance Health, Inc. | 10,164 | 70 | 1 | — | 9 | 2% |
| H7200 Amerigroup Tennessee, Inc. | Anthem Inc. | — | 71 | 2 | −1 | 8 | 3% |
| H0913 Wellcare | Centene Corporation | 12,667 | 71 | 2 | 0 | 8 | 3% |
| H3337 LIBERTY HEALTH ADVANTAGE, INC. | Liberty Health Advantage, Inc. | — | 71 | 2 | 0 | 8 | 3% |
| H0908 Wellcare | Centene Corporation | 8,453 | 71 | 2 | 0 | 8 | 3% |
| H0251 UnitedHealthcare | UnitedHealth Group, Inc. | 76,188 | 72 | 2 | 0 | 7 | 4% |
| H5475 Wellcare | Centene Corporation | 18,951 | 72 | 2 | 0 | 7 | 4% |
| H3054 Constellation Health, Llc. | Constellation Health, LLC. | — | 72 | 2 | 0 | 7 | 4% |
| H2879 Molina Healthcare of Wisconsin and Massachusetts | Molina Healthcare, Inc. | — | 72 | 2 | −3 | 7 | 4% |
| H3347 Elderplan | Elderplan, Inc. | 27,294 | 72 | 2 | 0 | 7 | 4% |
| H7173 Wellcare by Allwell | Centene Corporation | — | 72 | 2 | — | 7 | 4% |
| H3945 CIGNA HEALTH AND LIFE INSURANCE COMPANY | CIGNA | — | 72 | 2 | 0 | 7 | 4% |
| S1140 Highmark Blue Cross Blue Shield or Highmark Blue Shield | Highmark Health | 3,185 | 76 | 1 | 0 | 7 | 4% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2025 – 12/31/2025 | 3 | Prescription Drug Events |
| 2026 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2024 – 12/31/2024 | 3 | Prescription Drug Events |
| 2025 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2023 – 12/31/2023 | 3 | Prescription Drug Events |
| 2024 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2022 – 12/31/2022 | 3 | Prescription Drug Events |
| 2023 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2021 – 12/31/2021 | 3 | Prescription Drug Events |
| 2022 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2020 – 12/31/2020 | 3 | Prescription Drug Events |
| 2021 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2019 – 12/31/2019 | 3 | Prescription Drug Events |
| 2020 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2018 – 12/31/2018 | 3 | Prescription Drug Events |
| 2019 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2017 – 12/31/2017 | 3 | Prescription Drug Events |
| 2018 | D12 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2016 – 12/31/2016 | 3 | Prescription Drug Events |
| 2017 | D13 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2015 - 12/31/2015 | 3 | Prescription Drug Events |
| 2016 | D13 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2014 - 12/31/2014 | 3 | Prescription Drug Events |
| 2015 | D12 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2013 - 12/31/2013 | 3 | Prescription Drug Events |